SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2
about
Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitorsLersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1In vitro and ex vivo evaluations on transdermal delivery of the HIV inhibitor IQP-0410Current and emerging formulation strategies for the effective transdermal delivery of HIV inhibitorsAnti-human immunodeficiency virus type 1 activity of novel 6-substituted 1-benzyl-3-(3,5-dimethylbenzyl)uracil derivatives.In vitro microbicidal activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTI-resistant human immunodeficiency virus type 1Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1.Considerations and development of topical microbicides to inhibit the sexual transmission of HIV.New anti-HIV agents and targets.Human immunodeficiency virus type 2 reverse transcriptase activity in model systems that mimic steps in reverse transcription.Development of dual-acting pyrimidinediones as novel and highly potent topical anti-HIV microbicidesVaginal film drug delivery of the pyrimidinedione IQP-0528 for the prevention of HIV infection.Antiviral interactions of combinations of highly potent 2,4(1H,3H)-pyrimidinedione congeners and other anti-HIV agents.Clinical utility of current NNRTIs and perspectives of new agents in this class under development.Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy.Using modeling to help understand vaginal microbicide functionality and create better products.The next generation of HIV/AIDS drugs: novel and developmental antiHIV drugs and targets.Pharmacokinetic and Pharmacodynamic Evaluation following Vaginal Application of IQB3002, a Dual-Chamber Microbicide Gel Containing the Nonnucleoside Reverse Transcriptase Inhibitor IQP-0528 in Rhesus Macaques.Antiretroviral drug resistance in human immunodeficiency virus type 2.Novel compounds for the treatment of HIV type-1 infection.The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study.The structure-activity relationships of 2,4(1H,3H)-pyrimidinedione derivatives as potent HIV type 1 and type 2 inhibitors.Comparative evaluation of the inhibitory activities of a series of pyrimidinedione congeners that inhibit human immunodeficiency virus types 1 and 2.The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitro.Synthesis and biological evaluation of endocyclic 2',3'-didehydro-2',3'-dideoxymethanocarba adenosine.Synthesis and antiviral activity of 1,3-disubstituted uracils against HIV-1 and HCMV.Antiviral activity of 3-(3,5-dimethylbenzyl)uracil derivatives against HIV-1 and HCMV.Strategies in the Design of Antiviral Drugs
P2860
Q24652511-444DB902-8B34-454F-9658-44B2DFEC7AA3Q27663609-93F2F796-FA36-4BEE-B010-0A52DD55A2CCQ28533587-94A31C3B-DD92-4161-936C-71DF9E9412E9Q28545757-74D552A9-B022-4C2C-93AF-F658057CA210Q34145448-1A547A3A-D7BD-4B38-BD55-9255E79E636DQ34647446-084849C3-E7B7-46D3-9FA3-AA83928FB175Q34737582-EA27EBA0-4048-4260-933D-35D2AEA105FAQ34768558-8EDEA558-44B7-470B-A736-A051971DB4ACQ34944447-A393E28D-8CA7-4929-9AA0-B648AA0AA39CQ35149625-317CFFC0-81B2-4FAD-AC96-0DC4C004836AQ35364134-D504DFB8-CE6A-40F6-9A8A-5640CA357BA9Q35518190-79973DFE-92C6-402D-B964-8D60945C0A33Q35751916-A0B831A5-F4D7-4E28-9558-EFC5C1A9105FQ35842270-33A92727-3C64-4C1F-B4EB-E73C9EC6CD74Q35842525-26FF041A-E862-4359-B32D-F1D9524B97EEQ35913838-33105497-0289-4903-88F9-F4394D7586D5Q35917148-D3F4BA77-F9DE-4C4D-868A-52D9D06A7961Q36644657-724D2A5E-7429-459A-870C-AE09E3E0D14EQ37496287-9C067198-E418-4B25-8ABA-FFB81AB5E955Q37502492-96FA1A8C-61E0-451C-8DDE-BE39D156C751Q39852169-2C169036-11CF-4471-9C2C-E4A465AB1DF5Q40042904-7C3CA90A-CCF3-49C2-B8FB-F4A9FC78F902Q40060575-916D77AF-99F2-4438-AE0E-813092E13B6AQ42932779-F7BDE2CA-6CAD-433F-A7D2-C88FF6C923A4Q44262231-4AD52821-7078-45CD-BA1E-09332FB193F5Q44705799-6080F801-88AF-4EAB-97EC-DE7E7BA4271FQ46860653-D565471A-4881-48DD-8614-9623DF12BEB2Q56786281-BD55ADA8-41A8-42E7-9BAD-8B2328B01C32
P2860
SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
SJ-3366, a unique and highly p ...... IV-1) that also inhibits HIV-2
@ast
SJ-3366, a unique and highly p ...... IV-1) that also inhibits HIV-2
@en
SJ-3366, a unique and highly p ...... IV-1) that also inhibits HIV-2
@nl
type
label
SJ-3366, a unique and highly p ...... IV-1) that also inhibits HIV-2
@ast
SJ-3366, a unique and highly p ...... IV-1) that also inhibits HIV-2
@en
SJ-3366, a unique and highly p ...... IV-1) that also inhibits HIV-2
@nl
prefLabel
SJ-3366, a unique and highly p ...... IV-1) that also inhibits HIV-2
@ast
SJ-3366, a unique and highly p ...... IV-1) that also inhibits HIV-2
@en
SJ-3366, a unique and highly p ...... IV-1) that also inhibits HIV-2
@nl
P2093
P2860
P1476
SJ-3366, a unique and highly p ...... IV-1) that also inhibits HIV-2
@en
P2093
J A Turpin
L A Pallansch
M C Osterling
P2860
P304
P356
10.1128/AAC.45.2.393-400.2001
P407
P577
2001-02-01T00:00:00Z